Carmel Pharma

Survey Verifies Link Between Nurses' Illness and Occupational Exposure

Scientists recently released the results of the first ever national survey which assessed nurses’ extent and frequency of exposures to common health care hazards.

Columbus, OH, December 19, 2007 --( This survey substantiates that there are links between the duration and intensity of nurses' exposures to “chemicals, pharmaceuticals and radiation on the job and health problems they develop such as cancer, asthma, miscarriages and children's birth defects.” The survey included 1500 nurses from all 50 states.

The results are available online at from the Environmental Working Group, the American Nurses Association, Health Care without Harm and the Environmental Health Education Center at the University of Maryland School of Nursing. Results indicate that:

- 41% of the 1,500 nurses reported on the job exposures.
- 42% higher rates of cancer were reported for nurses who experience frequent, long-term exposure to chemotherapeutic medications through preparation and administration, than for other nurses.

The PhaSeal® System is a clinically proven closed-system drug transfer device that has proven to significantly reduce hazardous drug exposure within the environment of care. With over 14 peer-reviewed, independently published clinical studies to verify its efficacy, it is the only closed-system drug transfer device that maintains dry, leakproof connections and airtight containment throughout the preparation and administration phases of hazardous drug handling.

Currently over 500 cancer centers, oncology practices and specialty pharmacies use the PhaSeal System. “No other transfer device exists on the market today that meets the NIOSH and ISOPP definition of closed and therefore can provide the level of protection I want and expect for my staff,” says Jim Jorgenson Director of Pharmacy at the University of Utah.

For more information about the PhaSeal® System visit or call 866-487-9250 x202.

Carmel Pharma ab in Gothenburg, Sweden manufactures The PhaSeal System and distributes from its U.S. affiliate office, Carmel Pharma, Inc., in Columbus, OH. PhaSeal has been in use in the U.S. since 2000 and implemented in over 500 cancer centers, oncology practices, specialty pharmacies in the United States, including M.D. Anderson in Houston, TX, Texas Children’s and UCSF.

Carmel Pharma, Inc.
Christine Crooks